Compositon/Ingredients: Erythropoietin

- Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:

• Treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis

• Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.

- Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).

• Have uncontrolled hypertension.

• Develop pure red cell aplasia (PRCA) following treatment with erythropoietin

• Hypersensitivity to the active substance or to any of the excipients.

• Have surgery and cannot receive adequate antithrombotic prophylaxis for any reason.

• Have autologous blood predonation programmes

• Are scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation

• Suffer severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.

Store at temperature below 30°C, protect from light.